A detailed history of Vanguard Group Inc transactions in Ngm Biopharmaceuticals Inc stock. As of the latest transaction made, Vanguard Group Inc holds 2,324,392 shares of NGM stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,324,392
Previous 2,770,574 16.1%
Holding current value
$0
Previous $2.38 Million 55.12%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$1.17 - $1.92 $522,032 - $856,669
-446,182 Reduced 16.1%
2,324,392 $3.7 Million
Q4 2023

Feb 14, 2024

BUY
$0.6 - $1.31 $5,683 - $12,408
9,472 Added 0.34%
2,770,574 $2.38 Million
Q3 2023

Nov 14, 2023

SELL
$1.05 - $3.37 $33,765 - $108,372
-32,158 Reduced 1.15%
2,761,102 $2.95 Million
Q2 2023

Aug 14, 2023

SELL
$2.44 - $4.53 $2.16 Million - $4.01 Million
-885,263 Reduced 24.07%
2,793,260 $7.23 Million
Q1 2023

May 15, 2023

SELL
$3.72 - $5.4 $3.02 Million - $4.38 Million
-810,626 Reduced 18.06%
3,678,523 $15 Million
Q4 2022

Feb 10, 2023

BUY
$3.41 - $12.93 $2.01 Million - $7.63 Million
589,852 Added 15.13%
4,489,149 $22.5 Million
Q3 2022

Nov 14, 2022

BUY
$12.59 - $17.67 $6.25 Million - $8.77 Million
496,089 Added 14.58%
3,899,297 $51 Million
Q2 2022

Aug 12, 2022

BUY
$10.58 - $17.5 $4.11 Million - $6.8 Million
388,733 Added 12.9%
3,403,208 $43.6 Million
Q1 2022

May 13, 2022

BUY
$13.81 - $18.6 $652,356 - $878,626
47,238 Added 1.59%
3,014,475 $46 Million
Q4 2021

Feb 14, 2022

BUY
$17.26 - $22.02 $24.3 Million - $31 Million
1,407,112 Added 90.19%
2,967,237 $52.6 Million
Q3 2021

Nov 12, 2021

BUY
$20.15 - $26.19 $3.45 Million - $4.48 Million
171,051 Added 12.31%
1,560,125 $32.8 Million
Q2 2021

Aug 13, 2021

BUY
$15.06 - $30.03 $20.9 Million - $41.7 Million
1,389,074 New
1,389,074 $27.4 Million

Others Institutions Holding NGM

About NGM BIOPHARMACEUTICALS INC


  • Ticker NGM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,365,904
  • Description
  • NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...
More about NGM
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.